JP2002508183A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002508183A5 JP2002508183A5 JP2000539141A JP2000539141A JP2002508183A5 JP 2002508183 A5 JP2002508183 A5 JP 2002508183A5 JP 2000539141 A JP2000539141 A JP 2000539141A JP 2000539141 A JP2000539141 A JP 2000539141A JP 2002508183 A5 JP2002508183 A5 JP 2002508183A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- nucleic acid
- amino acids
- ulbp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 23
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 108020004707 nucleic acids Proteins 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical class [H]N([H])* 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6985797P | 1997-12-17 | 1997-12-17 | |
| US60/069,857 | 1997-12-17 | ||
| US9294698P | 1998-07-15 | 1998-07-15 | |
| US60/092,946 | 1998-07-15 | ||
| PCT/US1998/027048 WO1999031241A1 (en) | 1997-12-17 | 1998-12-17 | Cell surface glycoproteins associated with human b cell lymphomas - ulbp, dna and polypeptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002508183A JP2002508183A (ja) | 2002-03-19 |
| JP2002508183A5 true JP2002508183A5 (OSRAM) | 2006-02-02 |
| JP4255211B2 JP4255211B2 (ja) | 2009-04-15 |
Family
ID=26750491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000539141A Expired - Fee Related JP4255211B2 (ja) | 1997-12-17 | 1998-12-17 | ヒトｂ細胞リンパ腫に関連した細胞表面糖タンパク質−ｕｌｂｐ、ｄｎａ及びポリペプチド |
Country Status (12)
| Country | Link |
|---|---|
| US (7) | US6653447B1 (OSRAM) |
| EP (1) | EP1037991B1 (OSRAM) |
| JP (1) | JP4255211B2 (OSRAM) |
| AT (1) | ATE305510T1 (OSRAM) |
| AU (1) | AU742757C (OSRAM) |
| CA (1) | CA2315251A1 (OSRAM) |
| DE (1) | DE69831754T2 (OSRAM) |
| DK (1) | DK1037991T3 (OSRAM) |
| ES (1) | ES2251120T3 (OSRAM) |
| IL (2) | IL136621A0 (OSRAM) |
| NZ (1) | NZ505500A (OSRAM) |
| WO (1) | WO1999031241A1 (OSRAM) |
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020137890A1 (en) * | 1997-03-31 | 2002-09-26 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| CA2364941A1 (en) * | 1999-03-15 | 2000-09-21 | Takeda Chemical Industries, Ltd. | Novel protein and its use |
| WO2002062997A1 (fr) * | 2001-02-05 | 2002-08-15 | Takeda Chemical Industries, Ltd. | Nouvelle proteine et son utilisation |
| US6821522B2 (en) * | 2001-05-31 | 2004-11-23 | The Regents Of The University Of California | Tumor Therapy |
| US7364890B2 (en) | 2001-07-28 | 2008-04-29 | Midwest Research Institute | Thermal tolerant avicelase from Acidothermus cellulolyticus |
| MXPA04003057A (es) * | 2001-10-04 | 2005-06-20 | Immunex Corp | Proteina 4 de enlace ul16. |
| CA2483343A1 (en) * | 2002-04-22 | 2003-10-30 | Fred Hutchinson Cancer Research Center | Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions |
| AU2003270063A1 (en) * | 2002-09-04 | 2004-03-29 | The Trustees Of The University Of Pennsylvania | Immune cell receptor ligand and immune cell receptor |
| US9809654B2 (en) | 2002-09-27 | 2017-11-07 | Vaccinex, Inc. | Targeted CD1d molecules |
| EP1413316A1 (en) * | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| MXPA05010255A (es) * | 2003-03-24 | 2005-12-14 | Scripps Research Inst | Vacunas de adn contra crecimiento tumoral y metodos de uso de las mismas. |
| US7666417B2 (en) * | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| GB0403491D0 (en) * | 2004-02-17 | 2004-03-24 | Univ Cambridge Tech | Polypeptides, methods and means |
| US7998481B2 (en) | 2004-04-05 | 2011-08-16 | The Regents Of The University Of California | Modulation of NKG2D for treating or preventing solid organ allograft rejection |
| DK1732588T3 (da) | 2004-04-05 | 2009-10-12 | Univ California | Modulation af NKG2D |
| JP5774805B2 (ja) | 2004-11-29 | 2015-09-09 | セクエノム，インコーポレイティド | メチル化ｄｎａを検出する方法、及びキット |
| US9074013B2 (en) | 2004-11-29 | 2015-07-07 | Sequenom, Inc. | Means and methods for detecting methylated DNA |
| EP1909832A4 (en) * | 2005-06-29 | 2010-01-13 | Univ Miami | ANTIBODY IMMUNOCELL LIGAND FUSION PROTEIN FOR CANCER THERAPY |
| US7846712B2 (en) | 2006-06-01 | 2010-12-07 | Alliance For Sustainable Energy, Llc | L-arabinose fermenting yeast |
| WO2008103392A2 (en) | 2007-02-21 | 2008-08-28 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| US9611313B2 (en) | 2007-06-26 | 2017-04-04 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| US20110038865A1 (en) * | 2007-06-26 | 2011-02-17 | University Of Miami | Antibody- endostatin fusion protein and its variants |
| US8070021B2 (en) * | 2007-10-31 | 2011-12-06 | Momentive Performance Materials | Hydraulic container evacuator and method |
| EP2385980B1 (en) | 2009-01-08 | 2018-04-18 | Albert Einstein College of Medicine, Inc. | Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof |
| WO2011127418A1 (en) | 2010-04-09 | 2011-10-13 | Amgen Inc. | Btnl9 proteins, nucleic acids, and antibodies and uses thereof |
| WO2011130749A2 (en) | 2010-04-16 | 2011-10-20 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Identification of mutations in herpes simplex virus envelope glycoproteins that enable or enhance vector retargeting to novel non-hsv receptors |
| WO2012064743A2 (en) | 2010-11-08 | 2012-05-18 | The Johns Hopkins University | Methods for improving heart function |
| US10040853B2 (en) * | 2011-09-09 | 2018-08-07 | Fred Hutchinson Cancer Research Center | Methods and compositions involving NKG2D inhibitors and cancer |
| US10093705B2 (en) | 2011-09-13 | 2018-10-09 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for brown fat induction and activity using FNDC5 |
| US20130156808A1 (en) * | 2011-11-22 | 2013-06-20 | Stipan Jonjic | Vaccine comprising beta-herpesvirus |
| WO2014015148A1 (en) | 2012-07-19 | 2014-01-23 | Amgen Inc. | Human btnl3 proteins, nucleic acids, and antibodies and uses thereof |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| US9371352B2 (en) | 2013-02-08 | 2016-06-21 | Vaccinex, Inc. | Modified glycolipids and methods of making and using the same |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2015017529A2 (en) | 2013-07-31 | 2015-02-05 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules |
| WO2015035215A1 (en) | 2013-09-05 | 2015-03-12 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| JP6588024B2 (ja) | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| CA2935804A1 (en) | 2014-01-14 | 2015-07-23 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms |
| AU2015259053B2 (en) | 2014-05-16 | 2020-12-24 | Amgen Inc. | Assay for detecting Th1 and Th2 cell populations |
| US11117969B2 (en) * | 2014-12-05 | 2021-09-14 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified α1-α2 domains of NKG2D ligands |
| AU2015357578B2 (en) | 2014-12-05 | 2018-11-08 | Xyphos Biosciences Inc. | Insertable variable fragments of antibodies and modified a1-a2 domains of NKG2D ligands |
| EP3368157B1 (en) | 2015-10-29 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| BR112018015390A2 (pt) | 2016-01-27 | 2018-12-18 | Oncorus, Inc. | vetores virais oncolíticos e usos dos mesmos |
| WO2017218689A1 (en) | 2016-06-14 | 2017-12-21 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Expression of nkg2d activating ligand proteins for sensitizing cancer cells to attack by cytotoxic immune cells |
| WO2018006005A1 (en) | 2016-06-30 | 2018-01-04 | Oncorus, Inc. | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| WO2018112636A1 (en) | 2016-12-21 | 2018-06-28 | Creatus Biosciences Inc. | Method and organism expressing metschnikowia xylose transporters for increased xylose uptake |
| US10435721B2 (en) | 2016-12-21 | 2019-10-08 | Creatus Biosciences Inc. | Xylitol producing metschnikowia species |
| JP7672196B2 (ja) | 2017-03-14 | 2025-05-07 | アムジエン・インコーポレーテツド | 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節 |
| WO2019023483A1 (en) | 2017-07-26 | 2019-01-31 | Oncorus, Inc. | ONCOLYTIC VIRAL VECTORS AND USES THEREOF |
| US11865081B2 (en) | 2017-12-29 | 2024-01-09 | Virogin Biotech Canada Ltd. | Oncolytic viral delivery of therapeutic polypeptides |
| EP3775251A1 (en) | 2018-03-26 | 2021-02-17 | Amgen Inc. | Total afucosylated glycoforms of antibodies produced in cell culture |
| CN112074532B (zh) | 2018-03-27 | 2025-02-28 | 修普霍斯生物科学有限公司 | 结合非天然NKG2D受体的非天然NKG2D配体的修饰的α1-α2结构域 |
| WO2020051013A2 (en) * | 2018-08-24 | 2020-03-12 | The Trustees Of Columbia University In The City Of New York | Anti-cd33 and nkg2d ligand chimeras for treatment of myeloid malignancies |
| CA3152547A1 (en) | 2019-09-26 | 2021-04-01 | Amgen Inc. | Methods of producing antibody compositions |
| US20230273126A1 (en) | 2020-06-04 | 2023-08-31 | Amgen Inc. | Assessment of cleaning procedures of a biotherapeutic manufacturing process |
| JP2023548767A (ja) | 2020-10-15 | 2023-11-21 | アムジエン・インコーポレーテツド | 抗体製造方法における相対不対グリカン |
| WO2022261021A1 (en) | 2021-06-07 | 2022-12-15 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
| EP4413377A1 (en) | 2021-10-05 | 2024-08-14 | Amgen Inc. | Fc-gamma receptor ii binding and glycan content |
| US20250161413A1 (en) | 2022-02-16 | 2025-05-22 | Dana-Farber Cancer Institute, Inc. | Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof |
| WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
| AU2024256160A1 (en) | 2023-04-20 | 2025-10-02 | Amgen Inc. | Methods of determining relative unpaired glycan content |
| WO2025038600A1 (en) | 2023-08-14 | 2025-02-20 | Amgen Inc. | Methods for reducing yellow color |
| WO2025101820A1 (en) | 2023-11-08 | 2025-05-15 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4959314A (en) * | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
| USRE38824E1 (en) * | 1986-08-04 | 2005-10-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Antibodies against human herpes virus-6(HHV-6) and method of use |
| US5834229A (en) * | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| US5464771A (en) * | 1994-04-29 | 1995-11-07 | The United States Of America As Represented By The Secretary Of Agriculture | Biologically pure culture of Actinomyces viscosus strain used for the bioremediation of chlorinated hydrocarbons |
| US6060241A (en) * | 1996-04-05 | 2000-05-09 | Kieta Holding Sa | Compositions and methods relating to drug discovery and detection and treatment of gastrointestinal diseases |
| US5912415A (en) * | 1996-05-16 | 1999-06-15 | Regents Of The University Of Minnesota | Arabidopsis spindly gene, methods of identification and use |
| US20030068623A1 (en) * | 1997-06-16 | 2003-04-10 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
-
1998
- 1998-12-17 AT AT98964802T patent/ATE305510T1/de not_active IP Right Cessation
- 1998-12-17 JP JP2000539141A patent/JP4255211B2/ja not_active Expired - Fee Related
- 1998-12-17 CA CA002315251A patent/CA2315251A1/en not_active Abandoned
- 1998-12-17 DK DK98964802T patent/DK1037991T3/da active
- 1998-12-17 AU AU20045/99A patent/AU742757C/en not_active Ceased
- 1998-12-17 IL IL13662198A patent/IL136621A0/xx unknown
- 1998-12-17 DE DE69831754T patent/DE69831754T2/de not_active Expired - Lifetime
- 1998-12-17 WO PCT/US1998/027048 patent/WO1999031241A1/en not_active Ceased
- 1998-12-17 NZ NZ505500A patent/NZ505500A/xx unknown
- 1998-12-17 EP EP98964802A patent/EP1037991B1/en not_active Expired - Lifetime
- 1998-12-17 ES ES98964802T patent/ES2251120T3/es not_active Expired - Lifetime
-
2000
- 2000-03-13 US US09/524,100 patent/US6653447B1/en not_active Expired - Fee Related
- 2000-03-22 US US09/532,856 patent/US6458350B1/en not_active Expired - Lifetime
- 2000-06-07 IL IL136621A patent/IL136621A/en not_active IP Right Cessation
-
2002
- 2002-08-05 US US10/212,507 patent/US6774224B2/en not_active Expired - Fee Related
-
2004
- 2004-06-23 US US10/875,869 patent/US7193058B2/en not_active Expired - Fee Related
-
2006
- 2006-12-13 US US11/638,966 patent/US7427669B2/en not_active Expired - Fee Related
-
2008
- 2008-08-04 US US12/221,490 patent/US7807796B2/en not_active Expired - Fee Related
-
2010
- 2010-08-24 US US12/862,629 patent/US8410252B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002508183A5 (OSRAM) | ||
| Bringman et al. | Monoclonal antibodies to human tumor necrosis factors alpha and beta: application for affinity purification, immunoassays, and as structural probes | |
| CA2190371A1 (en) | Receptor for oncostatin m | |
| CA2318482A1 (en) | Il-18 receptors | |
| JP2002500886A5 (OSRAM) | ||
| Wippler et al. | The integrin alpha IIb-beta 3, platelet glycoprotein IIb-IIIa, can form a functionally active heterodimer complex without the cysteine-rich repeats of the beta 3 subunit. | |
| JP2002502589A5 (OSRAM) | ||
| KR20110069020A (ko) | 지혈 활성을 가지고 혈소판 응집을 유도할 수 있는 재조합 단백질 | |
| JP2005046146A5 (OSRAM) | ||
| JP2002508970A5 (OSRAM) | ||
| JP2002505843A5 (OSRAM) | ||
| RU2003106809A (ru) | Гены гомологичных иммунодоминантных белков ehrlichia canis в 28-килодальтон и их применение | |
| JP2002516103A5 (OSRAM) | ||
| Bond et al. | A mouse T cell product that preferentially enhances IgA production. II. Physicochemical characterization. | |
| JP2002514418A5 (OSRAM) | ||
| JP2002536018A5 (OSRAM) | ||
| WO2000023565B1 (en) | Novel neuropilin/growth factor binding and uses thereof | |
| Ehlert et al. | Novel C-terminally truncated isoforms of the CXC chemokine β-thromboglobulin and their impact on neutrophil functions | |
| JP2004532037A5 (OSRAM) | ||
| Hellwage et al. | Biochemical and functional characterization of the factor-H-related protein 4 (FHR-4) | |
| CA2439452A1 (en) | High-affinity antagonists of elr-cxc chemokines | |
| Ehlert et al. | Limited and Defined Truncation at the C Terminus Enhances Receptor Binding and Degranulation Activity of the Neutrophil-activating Peptide 2 (NAP-2): COMPARISON OF NATIVE AND RECOMBINANT NAP-2 VARIANTS (∗) | |
| RU2001117860A (ru) | ГЕНЫ ГОМОЛОГИЧНЫХ ИММУНОДОМИНАНТНЫХ БЕЛКОВ МАССОЙ 28-КИЛОДАЛЬТОН Ehrlichia canis И ИХ ПРИМЕНЕНИЕ | |
| Gull et al. | Heterologous expression, immunochemical and computational analysis of recombinant human interferon alpha 2b | |
| CN102775502A (zh) | α干扰素融合蛋白 |